Cencora, Inc.

Cencora's 36.4 P/E ratio stands sharply elevated against its defensive healthcare distribution peers, yet the RSI of 34.5 suggests the stock has fallen into oversold territory—an unusual disconnect. With a $62.4B market cap anchoring a pharmaceutical wholesaler, the valuation premium implies the market prices in substantial margin expansion or market consolidation gains. The modest 2.83% short float indicates limited squeeze risk, and the stock trading below its 52-week high despite oversold technicals suggests institutional caution about current fundamentals justifying that multiple. Either the market is pricing perfection into this defensive compounder, or recent weakness has created a genuine valuation trap for those chasing mean reversion.